Multiple Sclerosis – A Brief Overview of the Disease, Its Pharmacotherapy

Year : 2024 | Volume :01 | Issue : 01 | Page : –
By

Dr. Aayushi Jaiswal

  1. Research Scholar Indian Institute of Public Health ,Himayatsagar, Rajendranagar mandal, Hyderabad Telangana

Abstract

Multiple Sclerosis is an autoimmune disorder mostly affecting individuals aged between 20-40. In this disorder, the optic, vertebral, and central nervous system nerves are primarily impacted. It is a neurological condition that worsens over time and is characterized by inflammation and the breakdown of the sheath that surrounds and shields the nerve fiber. Common symptoms may include muscle weakness, numbness, tingling, fatigue, vertigo, tremor, vision complications, pain, Lhermitte sign, sexual dysfunction, muscle spasms, bladder problems, and bowel problems. Myelin around the axon composes White matter. Therefore in Multiple Sclerosis Lesions are formed around white matter. Generally, Autoreactive B- cells play an important role in Multiple Sclerosis. Many drugs are available which are used to slow or decrease the progression of but not cure the disease. Various drugs like Ocrelizumab (The MuSicalE STUDY), Bruton Tyrosine Kinase Inhibitor-Evobrutinib, Clemastine (ReBUILD STUDY), Ibudilast, and MD1003(biotin), are under trial which shows their action by acting on various target sites like B- cell, Oligodendrocytes, Toll-like receptor Macrophage migration, Acetyl Co-A carboxylase.

Keywords: Clinically isolated Syndrome, Relapse – Remitting Multiple Sclerosis, Lhermitte sign, Malonyl Co-A

[This article belongs to International Journal of Virus Studies(ijvs)]

How to cite this article: Dr. Aayushi Jaiswal. Multiple Sclerosis – A Brief Overview of the Disease, Its Pharmacotherapy. International Journal of Virus Studies. 2024; 01(01):-.
How to cite this URL: Dr. Aayushi Jaiswal. Multiple Sclerosis – A Brief Overview of the Disease, Its Pharmacotherapy. International Journal of Virus Studies. 2024; 01(01):-. Available from: https://journals.stmjournals.com/ijvs/article=2024/view=147158

References

  1. Sharp MK. Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. The New England journal of medicine. 2017 Apr 1;376(17):1692-.
  2. Multiple Sclerosis (MS): Types, symptoms, and causes ;Available from: https://www.medicalnewstoday.com/articles/37556.php
  3. Multiple Sclerosis: Causes: Genetics, Environment & More;Available from: https://www.healthline.com/health/multiple-sclerosis/possible-causes#environmental-causes
  4. Tests for Diagnosing MS?;Available from: https://www.healthline.com/health/multiple-sclerosis/tests-diagnose#lumbar-puncture
  5. Diagnosis of Multiple sclerosis ;Available from: https://www.nhs.uk/conditions/multiple-sclerosis/diagnosis/
  6. About Multiple Sclerosis ;Available from: https://www.roche.com/solutions/focus-areas/neuroscience/multiple-sclerosis
  7. Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, Nobuta H, Zhu A, Friessen M, Gerona R, von Büdingen HC, Henry RG, Hauser SL, Chan JR. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017 Dec 2;390(10111):2481-2489. doi: 10.1016/S0140-6736(17)32346-2.
  8. MD1003.Multiple Sclerosis News Today. ;Available from: https://multiplesclerosisnewstoday.com/md1003-for-multiple-sclerosis/
  9. Expanded Disability Status Scale (EDSS) / Functional Systems Score (FSS). MDCalc.;Available from: https://www.mdcalc.com/expanded-disability-status-scale-edss-functional-systems-score-fss
  10. Aubagio (teriflunomide). MS Trust. [cited 2019 Aug 19];Available from: https://www.mstrust.org.uk/a-z/aubagio-teriflunomide
  11. AUBAGIO® (teriflunomide) Official Site [Internet]. aubagio.com. ;Available from: https://products.sanofi.us/aubagio/aubagio.html
  12. Rebif (interferon beta-1a). Multiple Sclerosis News Today. ;Available from: https://multiplesclerosisnewstoday.com/rebif-interferon-beta-1a/
  13. Copaxone : National Multiple Sclerosis Society= ;Available from: https://www.nationalmssociety.org/Treating-MS/Medications/Copaxone
  14. Mavenclad : National Multiple Sclerosis Society ;Available from: https://www.nationalmssociety.org/Treating-MS/Medications/Mavenclad
  15. Genovese MC, Kaine JL, Lowenstein MB, Giudice JD, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, Sweiss NJ. Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study. Arthritis & Rheumatism. 2008 Sep;58(9):2652-61.
  16. DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, Kelsoe G, Tedder TF. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. The Journal of Immunology. 2008 Jan 1;180(1):361-71.
  17. Flynn JP, Gerriets V. Ocrelizumab. In Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Sep 18]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK547750/
  18. Wolinsky JS, Arnold DL, Brochet B, Hartung HP, Montalban X, Naismith RT, Manfrini M, Overell J, Koendgen H, Sauter A, Bennett I. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. The Lancet Neurology. 2020 Dec 1;19(12):998-1009.
  19. 19.Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple SclerosisXavier Montalban, M.D., Ph.D., Douglas L. Arnold, M.D., Martin S. Weber, M.D., Ivan Staikov, M.D., Ph.D., Karolina Piasecka-Stryczynska, M.D., Ph.D., Jonathan Willmer, M.D., Emily C. Martin, Ph.D., Fernando Dangond, M.D.,
  20. Evobrutinib Phase II Analysis – News | Merck . Available from: https://www.merckgroup.com/en/news/evobrutinib-14-10-2021.html
  21. Goldman SA, Kuypers NJ. How to make an oligodendrocyte.Development (2015) 142 (23): 3983–3995. https://doi.org/10.1242/dev.126409
  22. Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, Nobuta H, Zhu A, Friessen M, Gerona R, von Büdingen HC, Henry RG, Hauser SL, Chan JR. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017 Dec 2;390(10111):2481-2489. doi: 10.1016/S0140-6736(17)32346-2.
  23. 23.Walsh JC, Garrick R, Cameron J, McLeod JG. Evoked potential changes in clinically definite Multiple Sclerosis: a two year follow up study. J Neurol Neurosurg Psychiatry 1982; 45: 494–500.
  24. Niklas A, Sebraoui H, Hess E, Wagner A, Then Bergh F. Outcome measures for trials of remyelinating agents in multiple sclerosis: retrospective longitudinal analysis of visual evoked potential latency. Multiple Sclerosis Journal. 2009 Jan;15(1):68-74.
  25. Moccia M, De Stefano N, Barkhof F. Imaging outcome measures for progressive multiple sclerosis trials. Multiple Sclerosis Journal. 2017 Oct;23(12):1614-26.
  26. Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A. Phase 2 trial of ibudilast in progressive multiple sclerosis. New England Journal of Medicine. 2018 Aug 30;379(9):846-55.
  27. Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M, Huerga E, Miszkiel KA, Plant GT, Polman C, Rovaris M. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. The Lancet Neurology. 2007 Aug 1;6(8):677-86.
  28. Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, et al. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. New England Journal of Medicine. 2018 Aug 30;379(9):846–55.
  29. Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C, Lebrun-Frenay C, Labauge P, Brassat D, Toosy A, Laplaud DA. MD1003 (high-dose pharmaceutical-grade biotin) for the treatment of chronic visual loss related to optic neuritis in multiple sclerosis: a randomized, double-blind, placebo-controlled study. CNS drugs. 2018 Jul;32:661-72.
  30. A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis .Clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04711148
  31. Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis – Full Text View – Clinicaltrials.govClinicaltrials.gov.Availablefrom: https://classic.clinicaltrials.gov/ct2/show/NCT05054140
  32. Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis Clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT05147220
Regular Issue Subscription Review Article
Volume 01
Issue 01
Received April 24, 2024
Accepted May 18, 2024
Published May 21, 2024
Views: 32